Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Colonic Neoplasms 11Rectal Neoplasms 9Colorectal Neoplasms 9Stomach Neoplasms 5Liver Neoplasms 5Esophageal Neoplasms 5Pancreatic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Precancerous Conditions 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Sarcoma 2Salivary Gland Neoplasms 2Oropharyngeal Neoplasms 2Neoplasms 2Nasopharyngeal Neoplasms 2Mouth Neoplasms 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Laryngeal Neoplasms 2Kidney Neoplasms 2Hypopharyngeal Neoplasms 2Hodgkin Disease 2Head and Neck Neoplasms 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

trametinib 1dabrafenib 1atezolizumab 1Valganciclovir 1Tinzaparin 1Polymerase Chain Reaction 1Biopsy 14-phenylbutyric acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × Polymerase Chain Reaction × Gastrointestinal × Clear all
NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

University of California, San Diego

Phase 2 Withdrawn
GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡